RE:new board director - new money ideas.... TLT, just like any other company, plans ahead, months in advance.
There's a clear execution path regarding biotechs. Different strategies, but clear execution.
Even before they started Ph. 1B, Roger stated in a Midas Letter interview the reason why they would go all alone till Ph. 2. Because they knew they had something different regarding the mechanism of this molecule.
And as Eoganacht once indicated, TLT was brllliantly clever in selecting an indication that would not require a Ph. 3, but instead just a pivotal Ph. 2. No need either to IV, as per Dr. Jewett for TLD-1433.
It's very easy to raise the word "dilution" ad nauseam on this board every time there's a pp but reality check, unless you have revenues, you have no other way to get there if you want to retain control. So by being clever, TLT's strategy avoided us additional years of Ph. 3 and hundred of millions in Ph. 3 spendings as Ph. 3 require to enroll many more patients than a Ph. 2.
We've made it through here thanks mostly because things have been carefully planned, on all aspects. It's been a long road, parsed with many obstacles and challenges, but we executed with a laser focus.
Having taken the Venture Capital route, we would not have been on an exchange and would have given a lot on the control side.
We are all shareholders with an amazing low entry cost, with lots of upside room to grow. And some still whine instead of seeing this as an amazing opportunity! Roger could have privatized TLT many years ago and this biotech would have re-entered at a much higher price today. But we would be owing no shares.
FDA Breakthrough designation will bring us credibility and visibility, which will help us in our jv discussions. With superior data, market valuation will take care of itself in due time.
We have:
- holy grail treatment with 6 well sought after attributes
- we have superior data
- we're now executing the Commercialization phase
Good times ahead.